Human T cells resistant to complement lysis by bivalent antibody can be efficiently lysed by dimers of monovalent antibody

Blood

Volumn 100, Issue 12, 2002, Pages 4067-4073

  Nielsen, Soren U ^a   Routledqe, Edward G ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; ANTIBODY; BIVALENT ANTIBODY; CD3 ANTIGEN; COMPLEMENT; DIMER; IMMUNOGLOBULIN ANTIBODY; IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN HEAVY CHAIN; IMMUNOGLOBULIN LIGHT CHAIN; MEMBRANE ANTIGEN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD3; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIGEN EXPRESSION; ARTICLE; BINDING AFFINITY; BLAST CELL; CARBOXY TERMINAL SEQUENCE; COMPLEMENT ACTIVATION; COMPLEMENT DEPENDENT CYTOTOXICITY; CONTROLLED STUDY; CROSS LINKING; CYTOLYSIS; DIMERIZATION; GENE EXPRESSION; GENETIC ENGINEERING; GUINEA PIG; HUMAN; HUMAN CELL; IMMUNOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; RABBIT; T CELL LEUKEMIA; T LYMPHOCYTE;

EID: 0036893364     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2002-03-0731     Document Type: Article

References (31)

1. Clark M, Bindon C, Dyer M, et al. The improved lytic function and in vivo efficacy of monovalent monoclonal antibodies. Eur J Immunol. 1989;19: 381-388.
2. Dyer M, Hale G, Marcus R, Waldmann H. Remission induction in patients with lymphoid malignancies using unconjugated CAMPATH-1 monoclonai antibodies. Leuk Lymphoma. 1990;2:179-193.
3. Dyer MJS, Hale G, Hayhoe FGJ, Waldmann H. Effects of CAMPATH-1 antibodies in vivo in patients with lymphoid malignancies: Influence of antibody isotype. Blood. 1989;73:1431-1439.
4. Gorman SD, Clark MR. Humanization of monoclonal antibodies for therapy. Semin Immunol. 1990;2:457-466.
5. Isaacs JD. The antiglobulin response to therapeutic antibodies. Semin Immunol. 1990;2:449-456.
6. Bruggemann M, Williams GT, Bindon CI, et al. Comparison of the effector functions of human immunoglobulins using a matched set of chimeric antibodies. J Exp Med. 1987;166:1351-1361.
7. Circolo A, Battista P, Borso T. Efficiency of activation of complement by anti-hapten antibodies at the red cell surface; effect of patchy vs random distribution of hapten. Mol Immunol. 1985;22:207-214.
8. Bindon CI, Hale G, Waidmann H. Importance of antigen specificity for complement-mediated lysis by monoclonal antibodies. Eur J Immunol. 1988; 18:1507-1514.
9. Michaelsen TE, Garred P, Aase A. Human IgG subclass pattern of inducing complement-mediated cytolysis depends on antigen concentration, and to a lesser extent on epitope patchiness, antibody affinity and complement concentration. Eur J Immunol. 1991;21:11-16.
10. Gordon J, Stevenson GT. Antigenic modulation of lymphocyte surface immunoglobulin yielding resistance to complement-mediated lysis, II: Relationship to redistribution of the antigen. Immunology. 1981;42:13-17.
11. Scheinberg DA, Lovett D, Divgi CR, et al. A phase I trial of monoclonal antibody M195 in acute myelogenous leukemia: Specific bone marrow targeting and internalization of radionuclide. J Clin Oncol. 1991;9:478-490.
12. Henell KR, Bakke A, Kenny TA, Kimball JA, Barry JM, Norman DJ. Degree of modulation of cell-surface CD3 by anti-lymphocyte therapies. Transplant Proc. 1991;23:1070-1071.
13. Glennie MJ, Stevenson GT. Univalent antibodies kill tumour cells in vitro and in vivo. Nature. 1982; 295:712-714.
14. Cobbold SP, Waldmann H. Therapeutic potential of monovalent monoclonal antibodies. Nature. 1984;308:460-462.
15. Routledge EG, Lloyd I, Gorman SD, Clark M, Waldmann H. A humanized monovalent CD3 antibody which can activate homologous complement. Eur J Immunol. 1991;21:2717-2725.
16. Shopes B. A genetically engineered human IgG mutant with enhanced cytolytic activity. J Immunol. 1992;148:2918-2922.
17. Caron PC, Laird W, Co MS, Avdalovic NM, Queen C, Scheinberg DA. Engineered humanized dimeric forms of IgG are more effective antibodies. J Exp Med. 1992;176:1191-1195.
18. Greenwood J, Gorman SD, Routledge EG, Lloyd IS, Waldmann H. Engineering multiple-domain forms of the therapeutic antibody CAMPATH-1 H: Effects on complement lysis. Ther Immunol. 1994; 1:247-255.
19. Kabat EA, Wu TT, Reid-Miller M, Perry HM, Gottesman KS. Sequences of Proteins of Immunological Interest. 4th Ed. Bethesda, MD: US Department of Health and Human Services, Public Health Service, National Institutes of Health; 1987.
20. Bebbington C. Use of vectors based on gene amplification for the expression of cloned genes in mammalian cells. In: Glover DM, Hames BD, eds. DNA Cloning 4. 2nd Ed. Oxford, England: IRL Press; 1995:85-112.
21. Harlow E, Lane L. Antibodies, a Laboratory Manual. New York; NY: Cold Spring Harbor Laboratory Press; 1988.
22. 2 antibody containing thioether-linked Fab'γy fragments. J Immunol. 1987;139:2367-2375.
23. Stevenson GT, Pindar A, Slade CJ. Achimaeric antibody with dual Fc regions (bis FabFc) prepared by manipulations of the IgG hinge. Anticancer Drug Des. 1989;3:219-230.
24. Stalteri MA, Mather SJ. A cross-linked monoclonal antibody fragment for improved tumor targeting. Bioconj Chem. 1995;6:179-186.
25. Riechmann L, Clark M, Waldmann H, Winter G. Reshaping human antibodies for therapy. Nature. 1988;332:323-327.
26. Naume B, Nonstad U, Steinkjer B, Funderud S, Smeland E, Espevik T. Immunomagnetic isolation of NK and LAK cells. J Immunol Methods. 1991; 136:1-9.
27. Miller JS, Oelkers S, Verfaillie C, McGlave P. Role of monocytes in the expansion of human activated natural killer cells. Blood. 1992;80:2221-2229.
28. 2 antibody for the delivery ofsaporin in the treatment of lymphoma. J Immunol. 1988;141:3662-3670.
29. Meri S, Morgan BP, Davies A, et al. Human protectin (CD59), an 18,000-20,000 MW complement lysis restricting factor, inhibits C5b-8 catalyzed insertion of C9 into lipid bilayers. Immunology. 1990;71:1-9.
30. Burton DR. Is IgM-like dislocation a common feature of antibody function? Immunol Today. 1986; 7:165-167.
31. Oi VT, Vuong TM, Hardy R et al. Correlation between segmental flexibility and effector function. Nature. 1984;307:136-140.